NCT04389229 - OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial) | Biotech Hunter

Timeline

Start Date

July 1, 2020

Primary Completion Date

March 31, 2023

Study Completion Date

July 31, 2025

Conditions

Ovarian Cancer Metastatic

Interventions

DRUG

cyclophosphamide

600mg/m2/day for 3 days ( on day -5, -4, -3)

DRUG

fludarabine

30mg/m2/day for 3 days ( on day -5, -4, -3)

DRUG

IL-2 (Proleukin)

Subcutaneous injections at a fixed dose of 18 million units once a day following TIL infusion

GENETIC

Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)

Single dose at 5 x 10\^9 - 5 x 10\^10

GENETIC

Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)

Single dose at 2 x10\^9 (+/- 20%) (engineered TIL)

Trial Locations (2)

Queens Elizabeth Hospital, Birmingham

The Christies Hospital, Manchester